NCT06066606 U-LABA/ICS Effects on Exercise Performance, Vilanterol
| NCT ID | NCT06066606 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Morten Hostrup, PhD |
| Condition | Exercise Performance |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-10-03 |
| Primary Completion | 2026-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-10-03 with a primary completion date of 2026-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
Eligibility Criteria
Inclusion Criteria: * Age 18-39 * Physically active \> 5 h weekly * Maximal oxygen consumption classified as high or very high Exclusion Criteria: * Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid * ECG abnormality * ACQ score \> 1.5 * Severe bronchial hyperreactivity as determined by mannitol test * FEV1/FVC ratio \< 0.7 determined with spirometry * Chronic illness determined to be a potential risk for participant during study * In chronic treatment with medication that may interfere with study results * Pregnancy * Smoker * Blood donation during the past 3 months
Contact & Investigator
Morten Hostrup, PhD
PRINCIPAL INVESTIGATOR
University of Copenhagen
Frequently Asked Questions
Who can join the NCT06066606 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Exercise Performance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06066606 currently recruiting?
Yes, NCT06066606 is actively recruiting participants. Contact the research team at mhostrup@nexs.ku.dk for enrollment information.
Where is the NCT06066606 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT06066606 clinical trial?
NCT06066606 is sponsored by Morten Hostrup, PhD. The principal investigator is Morten Hostrup, PhD at University of Copenhagen. The trial plans to enroll 30 participants.